Hone Health Raises $228M in Funding, Backed by MarcyPen and Kinship Ventures

Top Picks
Submit PRStay Ahead of the Market
Get the latest startup funding, hiring trends and global opportunities delivered to your inbox every week.
Hone Health, a US-based longevity and preventative healthcare company, has secured $228 million in funding, including $28 million in Series A equity and $200 million in growth funding from General Catalyst's Customer Value Fund (CVF). The round was led by MarcyPen, the investment firm associated with Jay-Z and Jay Brown, with participation from Kinship Ventures, co-founded by Gwyneth Paltrow, alongside several other investors.
Founded by Saad Alam, Hone Health combines diagnostic testing, physician-led care and AI-powered health insights. The company aims to help patients better understand their health data and access ongoing care focused on preventative health and longevity.
The funding will support the development of its Longevity OS platform, expansion into additional healthcare areas, broader diagnostic capabilities and clinical trials. The company also plans to invest in areas including metabolic health and polycystic ovary syndrome (PCOS).
A $228 Million Raise With Two Different Funding Components
The funding package comprises two distinct components: $28 million in Series A equity and $200 million in growth funding from General Catalyst's Customer Value Fund.
The distinction is important because the headline $228 million does not represent a single equity investment. The equity component follows Hone's previously announced $33 million Series A round in January 2025. According to the report, MarcyPen also led that earlier round, bringing the company's reported total equity funding to $65 million before the latest financing.
General Catalyst's Customer Value Fund has also backed other healthcare businesses, including Function Health, which received $450 million from the fund in July 2026.
Building a Longevity-Focused Healthcare Platform
Hone Health was founded after Alam experienced difficulty obtaining answers about his own health concerns. He has said that finding doctors who could diagnose his hormone imbalance took approximately a year.
The company was built around the idea of combining detailed diagnostics with continuing physician guidance. Rather than positioning itself solely as a virtual care provider, Hone aims to give patients access to testing, medical oversight and insights that can inform longer-term health decisions.
Alam says the company generated more than $100 million in recurring revenue last year and has served approximately 200,000 patients. The business has around 450 employees, including doctors, and currently operates in the United States.
The company reported treating 55,000 patients in January 2025, indicating substantial growth in its reported patient base since then.
Hone Black and Expanded Diagnostic Services
Alongside its funding announcement, Hone is preparing to launch Hone Black, a concierge membership that has been in development for approximately a year.
The membership offers testing across more than 1,600 markers and includes access to additional services and therapies, such as peptides, exosomes and stem cell treatments.
However, some of these offerings carry regulatory considerations. The US Food and Drug Administration has warned that exosome products intended for use in humans are not approved for the treatment of diseases or conditions. The regulatory status of compounded peptide products also requires careful consideration. These therapies should not be presented as established or FDA-approved treatments simply because they appear in a commercial membership offering.
Celebrity Investors and Institutional Backing
MarcyPen led the round. The firm was formed in December 2024 through the combination of Jay-Z's Marcy Venture Partners and Pendulum Holdings' investment arm. Jay Brown is a co-founder and managing partner.
Kinship Ventures, co-founded by actor and entrepreneur Gwyneth Paltrow, also participated. The investment group focuses on businesses in the consumer and wellness sectors.
Other participants named in the report include musicians Nick, Joe and Kevin Jonas, Kelly Rowland, actor Marcello Hernandez, NFL player Braxton Berrios, Knicks owner Quentin Dolan, Kyle Samani and Halle Tecco. Institutional investors include Hanwha, Gannet Capital, humbition and Comma Capital.
Pentland Ventures also appears in the company's investor commentary, with investment manager Omar Hatteea highlighting Hone's combination of diagnostics and ongoing physician relationships.
Expanding Into New Areas of Preventative Care
Hone plans to deploy the new capital towards its Longevity OS platform, expanded diagnostics, clinical trials and additional healthcare categories, including metabolic care and PCOS.
The company also intends to develop its role beyond virtual consultations by conducting clinical trials and commercialising medicines. This ambition would move Hone further into the development and delivery of longevity-focused healthcare products and services.
Hone is frequently compared with Hims & Hers, although Alam positions the company's focus around longevity and reducing biological age. The company has also added whole-body MRI services through Prenuvo, expanding its diagnostic offering.
With its latest funding, Hone is seeking to scale a model that brings diagnostics, physician-led care and technology into a longer-term healthcare relationship. Its ability to expand this approach while navigating the regulatory requirements around emerging therapies will be an important part of its next phase.
Have a Funding Round or Exciting Update to Share?
Submit your press release to get featured on WorkNation and reach founders, investors, and tech leaders.









